CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...
Phase 2
Chicago, Illinois, United States and 63 other locations
in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...
Phase 3
Chicago, Illinois, United States and 209 other locations
N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study ...
Phase 2
Chicago, Illinois, United States and 8 other locations
works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high leve...
Phase 3
Hinsdale, Illinois, United States of America and 21 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Chicago, Illinois, United States and 122 other locations
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...
Phase 2, Phase 3
Chicago, Illinois, United States and 58 other locations
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...
Phase 3
Chicago, Illinois, United States and 230 other locations
in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...
Phase 3
Niles, Illinois, United States and 249 other locations
In this study, patients with small cell or non-small cell lung cancer will receive ADI...
Phase 1, Phase 2
Chicago, Illinois, United States and 2 other locations
and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...
Phase 1
Chicago, Illinois, United States and 30 other locations
Clinical trials
Research sites
Resources
Legal